ECFS 2020 - Optimizing pharmaceutical care in cystic fibrosis

European Cystic Fibrosis Society   179  OPTIMIZING PHARMACEUTICAL CARE IN CYSTIC FIBROSIS EVALUATION AND MANAGEMENT OF BETA-LACTAM ANTIBIOTIC DRUG REACTIONS CHAPTER 10 [21] Lammintausta K, Kortekan- gas-Savolainen O. The usefulness of skin tests to prove drug hypersensi- tivity. The British journal of derma- tology. 2005;152(5):968-74. [22] Blanca-Lopez N, Zapatero L, Alonso E, Torres MJ, Fuentes V, Marti- nez-Molero MI, et al. Skin testing and drug provocation in the diag- nosis of nonimmediate reactions to aminopenicillins in children. Allergy. 2009;64(2):229-33. [23] Pichler WJ, Tilch J. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy. 2004;59(8):809-20. [24] Whitaker P, Meng X, Lavergne SN, El-Ghaiesh S, Monshi M, Earnshaw C, et al. Mass spectrometric character- ization of circulating and functional antigens derived from piperacillin in patients with cystic fibrosis. J Immunol. 2011;187(1):200-11. [25] Romano A, Atanaskovic-Markovic M, Barbaud A, Bircher AJ, Brockow K, Caubet JC, et al. Towards a more precise diagnosis of hypersensitivity to beta-lactams - an EAACI position paper. Allergy. 2019. [26] Moss R. Sensitization to aztreonam and cross-reactivity with other beta- lactam antibiotics in high-risk patients with cystic fibrosis. J Allergy Clin Immunol. 1991;87(1 Pt 1):78-88. [15] Caimmi S, Sanfiorenzo C, Caimmi D, Bousquet PJ, Chiron R, Demoly P. Comprehensive allergy work-up is mandatory in cystic fibrosis patients who report a history suggestive of drug allergy to beta-lactam antibiotics. Clin Transl Allergy. 2012;2(1):10. [16] Romano A, Gaeta F, Valluzzi RL, Zaffiro A, Caruso C, Quaratino D. Natural evolution of skin-test sensi- tivity in patients with IgE-mediated hypersensitivity to cephalosporins. Allergy. 2014;69(6):806-9. [17] Brockow K, Garvey LH, Aberer W, Atanaskovic-Markovic M, Barbaud A, Bilo MB, et al. Skin test concentra- tions for systemically administered drugs -- an ENDA/EAACI Drug Allergy Interest Group position paper. Allergy. 2013;68(6):702-12. [18] Mayorga C, Celik G, Rouzaire P, Whitaker P, Bonadonna P, Rodrigues-Cernadas J, et al. In vitro tests for drug hypersensitivity reac- tions: an ENDA/EAACI Drug Allergy Interest Group position paper. Allergy. 2016;71(8):1103-34. [19] Barbaud A, Goncalo M, Bruynzeel D, Bircher A. Guidelines for performing skin tests with drugs in the inves- tigation of cutaneous adverse drug reactions. Contact Dermatitis. 2001;45(6):321-8. [20] Padial A, Antunez C, Blanca-Lopez N, Fernandez TD, Cornejo-Garcia JA, Mayorga C, et al. Non-immediate reactions to beta-lactams: diag- nostic value of skin testing and drug provocation test. Clin Exp Allergy. 2008;38(5):822-8.